Radovich M, Solzak JP, Wang CJ, Hancock BA, et al. Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer. Clin Cancer Res 2022 May 12. pii: 698879. doi: 10.1158/1078-0432.CCR-21-3078.
PMID: 35551360